Fennec Pharma’s partner Norgine Pharma launches Pedmarqsi in Germany: Monday, February 10, 2025, 14:00 Hrs [IST] Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceutica ...

Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company with a market capitalization of $183 million, announced today that their partner, Norgine Pharmaceuticals Ltd., has launched PEDMARQSI ...

Performance for Guardian Canadian Focused Equity Fund, Series A for the period ended December 31, 2024, is as follows: 1-year, 36.71%; 3-years, 17.42%; 5-years, 13.42%; and since inception, 11.31% ...

Detailed price information for Fennec Pharmaceuticals Inc (FRX-T) from The Globe and Mail including charting and trades.